Myomo Inc

Myomo Inc. beats revenue expectations in Q4 2025 but reports a deeper-than‑expected loss, highlighting ongoing challenges and the need for cost‑control and clinical breakthroughs.

Myomo Inc.’s stock plummeted 41% after its Q2 2025 earnings report, despite beating revenue expectations, due to a significant cut in revenue guidance and operational challenges.

Myomo Inc. reported a significant increase in sales, but fell short of profit targets, leading to a dip in its stock price and raising concerns about the company’s financial health.